Paul is a founder and the CEO of Phylogica and is the principle inventor of Phylogica’s drug discovery technologies. He has published 45 peer reviewed papers, and has filed more than 19 patent applications many of which are granted in the US and Europe. Specialising in drug discovery biotechnology and experimental genetics, he has attracted over A$5 million in research funding from Australia and the United States to develop the technology underpinning Phylogica.
Previously Paul founded InfaMed Ltd., now owned by Cambridge, UK-based Avita Medical Ltd, which is commercialising an FDA-approved/CE-marked paediatric drug delivery device that he invented and is currently being marketed internationally. He was also an Honorary Research Fellow at the Telethon Institute for Child Health Research, Perth, Western Australia and was appointed Adjunct Professor at the School of Paediatrics and Child Health of the University of Western Australia.
Paul carried out postdoctoral research in yeast genetics at Harvard and Oxford Universities where he discovered and characterised proteins involved in maintaining genome stability. He has a DPhil in Molecular Biology from Oxford University and BSc (Hons) from the University of Western Australia.
Nick Woolf, MA (Oxon), FCCA CFO and VP Corporate Development
Nick has over 15 years experience in the biotechnology sector, working both in industry and investment banking. Most recently, he was Chief Business Officer at Oxford BioMedica plc, a leading UK gene therapy company. Previously, Nick was a highly rated biotechnology equity analyst in Europe. In investment banking he has worked at ABN AMRO as Head of European Biotechnology Research and held similar roles at BancAmerica Robertson Stephens, Nomura and SBC Warburg.
Nick is a qualified accountant and has an MA in Chemistry from the University of Oxford.
Dr Richard Hopkins, BSc (Hons), PhD COO and VP Research
Richard is a founder of Phylogica and is currently the COO and VP of Research. His most recent research is focussed on engineering peptide leads for drug development. He has published over 20 peer reviewed papers and is a co-inventor on over 10 patent applications, several of which have been issued in the US and Europe.
Previously Richard carried out postdoctoral research in yeast genetics at the Telethon Institute for Child Health Research, Perth, Western Australia. His research focussed on the development of a novel class of peptides, trademarked by Phylogica as Phylomers®, and the methods to integrate them into various high throughput screening platforms such as yeast- two-hybrid and phage display.
Richard has a BSc (Hons) and completed a PhD in Molecular Parasitiology.
Paul is a founder and the CEO of Phylogica and is the principle inventor of Phylogica’s drug discovery technologies. He has published 45 peer reviewed papers, and has filed more than 19 patent applications many of which are granted in the US and Europe. Specialising in drug discovery biotechnology and experimental genetics, he has attracted over A$5 million in research funding from Australia and the United States to develop the technology underpinning Phylogica.
Nick has over 15 years experience in the biotechnology sector, working both in industry and investment banking. Most recently, he was Chief Business Officer at Oxford BioMedica plc, a leading UK gene therapy company. Previously, Nick was a highly rated biotechnology equity analyst in Europe. In investment banking he has worked at ABN AMRO as Head of European Biotechnology Research and held similar roles at BancAmerica Robertson Stephens, Nomura and SBC Warburg.
Richard is a founder of Phylogica and is currently the COO and VP of Research. His most recent research is focussed on engineering peptide leads for drug development. He has published over 20 peer reviewed papers and is a co-inventor on over 10 patent applications, several of which have been issued in the US and Europe.